Variables | |
Gender ratio, F:M | 15:3 |
Onset age (y), mean ± SD | 40.28 ± 18.57 |
Disease duration (m), median (IQR) | 30.50 (17.50–44.75) |
Onset symptoms | |
Ocular, n (%) | 11 (61.11) |
Bulbar, n (%) | 10 (55.56) |
Limbs, n (%) | 7 (38.89) |
Serum MuSK-ab titer (nmol/L) at diagnosis, mean ± SD | 1.50 ± 2.80 |
RNS test positive | |
Musculus deltoideus, n (%) | 15 (83.33) |
Trapezius, n (%) | 8 (44.44) |
Orbicular oculi, n (%) | 12 (66.67) |
Abductor digiti minimi, n (%) | 3 (16.67) |
Any muscles | 15 (83.33) |
Pyridostigmine test positive, n (%) | 11 (61.11) |
Thymic abnormalities on chest CT, n (%) | 3 (16.67) |
Symptoms involved over the disease course | |
Ocular, n (%) | 13 (72.22) |
Bulbar, n (%) | 16 (88.89) |
Limbs, n (%) | 7 (38.89) |
Myasthenic crisis, n (%) | 5 (27.78) |
QMGs before therapy, mean ± SD | 12.83 ± 5.61 |
QMGs at last follow-up, mean ± SD | 0.17 ± 0.51 |